The primary aim of this project is to develop and validate technologies for the physical, chemical and optical characterisation of nanomaterials in biological matrices. Direct impact will result from the establishment of this new measurement capability within the NMIs themselves. Outside of the immediate consortium, wider target beneficiaries for the project are:
- Nanobiotechnology and nanomedicine organisations, who will benefit from standard materials and validated protocols with which to perform their analyses
- Regulatory and legislative bodies who will be able to make decisions and recommendations based upon from coherent and comparable data
- Manufacturers of nanomaterials who will benefit from a standards and regulatory framework that is fit for purpose and does not impose unmerited restrictions.